Member Info for matarakz

NEW – PathFlow™ Rapid Tests

The new PathFlow™ range of products will quickly expand to become your complete solution for the rapid diagnoses of Infectious Diseases…

Are they launching Lateral Rapid Antibody test?

Odx and avacta all are speculative. Imho , they would even struggle to sell covid products worth £40 million a year.

I bought this because of the company’ s fundamentals. I believe rns update would be next month. I do not expect rns everyday every week because i am not a day trader here.

France is 4% up now!

We are blue, hopefully it would hold today! The fundamentals of the company are very strong. More than £150 million by year end net profit imho. Gla

Imho we already hit the bottom hopefully

Yes ,it was up 11% in Nasdaq.
Hopefully it would be better today.

Indeed, odx is only part of the consortium amd yet it is almost £100 million cap.

Someone bought 700,000 shares !

I’m long term holder here. My target is still the same £10 by year end. Imho by year end we would have at least £150 million profit after tax.

Blue is coming soon!

Have we hit the bottom? Hopefully the forward seller is finished now imho.

I did my research here, the company has already products which are candidates for phase 3, Novartis is also an investor. Comparing this to its peer, imho the market cap should be at least £50O million.

It’s blue now!

That was a good rns, able to raise money and now Amapa is looking better now. Gla

That was a premature old study - may 2020
The latest study is not a good result.

Scientists have found after studying the plasma of 149 people who had Coronavirus, around 80% of people produced only tiny amounts of antibodies.

A third had undetectable levels.

Antibody tests will not provide an immunity passport. I'm sure other immune mechanisms are at play
Twitted by Professor Karol Sikora

https://www.biorxiv.org/content/10.1101/2020.05.13.092619v2
Not good news for Antibody test

My personal revenue projection for year end is £450 million to £600 million with gross profit of £200-250 million imho.

Only few Aim companies can emulate the success of Novacyt.

Debt free
No dilution
Only 70 million shares
Directors - buying shares
Plenty of cash

Hopefully launching of new products and US update next week imho.Gl